Generic Rx Delays Could Result From House Medicare Provisions, GPhA Says

A provision on the "antibundling" of generic drug applications in the House Medicare prescription drug bill could be misused by the brand name industry to delay the market entry of generics, the Generic Pharmaceutical Association says

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet